MENTAL HEALTH RESEARCH CENTER STUDY OF SCHIZOPHRENIA

MHCRC将促进合作研究关系，并作为催化剂 对于从事多学科研究的研究人员来说， 精神分裂症的脆弱性/压力概念。 MHCRC的结构是 作为一组核心实验室， 管理，临床和行政服务，7个核心和几个 附属研究项目。 MHCRC核心实验室包括家庭 评估和治疗，社交技能， 认知心理生理学神经心理学，临床精神药理学， 和诊断/精神病理学评估。 实验室和单位进行 “研究与发展”工作并提供评估和诊断服务， 独立资助的研究项目。 由核心进行的研究 实验室、单位和项目由共同的脆弱性/压力联系在一起 精神分裂症的概念和多层次研究的指导下， 环境、心理和生物变量。 内省 脆弱性因素，人际和家庭调节， 促进因素和应激源，加速或加重症状 在相关性、交互性、治疗性和纵向方面进行评价 问题研究 这些研究的结果将提供有关复发的信息， 缓解，并允许设计更有针对性的干预战略， 精神分裂症的预防和治疗。 的功效 至少三种创新的治疗方法，结合联合收割机的心理社会和 将记录药物治疗元素;社交技能培训和 家庭治疗方法已被验证将被“包装”， 手册中的传播。 将制定预测程序， 有复发高风险的患者， 具体形式的家庭教育和治疗。 将加强 在评估社会技能结构的技术上。 精神分裂 将确定接受低剂量长效制剂最佳治疗的患者 氟奋乃静及其对试验剂量的早期反应的评价 用来预测他们的长期结果。 一项纵向多水平研究 目的是阐明预测复发、缓解模式的变量， 和生活质量;和传播的变量，标志着特质， 与精神分裂症症状有关的脆弱性。

The MHCRC will foster collaborative research ties and serve as a catalyst for investigators pursuing multidisciplinary research on a vulnerability/stress conception of schizophrenia. The MHCRC is structured as a set of core laboratories providing assessment, diagnostic, data management, clinical, and administrative services to 7 core and several affiliated research projects. Core MHCRC laboratories include family assessment and treatment, social skills, cognitive-psychophysiology-neuropsychology, clinical psychopharmacology, and diagnosis/psychopathology assessment. Laboratories and units conduct "R and D" work and offer assessment and diagnostic services to independently funded research projects. The research carried out by core laboratories, units and projects is united by a common vulnerability/stress conception of schizophrenia and guided by multilevel study of environmental, psychological, and biological variables. Intrapersonal vulnerability factors, interpersonal and familial moderating and potentiating factors, and stressors that precipitate or exacerbate symptoms are evaluated in correlational, interactional, treatment, and longitudinal studies. The results of these studies will give information on relapse and remission and permit the design of more focused intervention strategies for prevention and treatment of schizophrenic disorders. The efficacy of at least three innovative treatment methods that combine psychosocial and pharmacotherapy elements will be documented; social skills training and family therapy methods that have been validated will be "packaged" for dissemination in manuals. Procedures will be developed for predicting patients who are at high risk for relpase and would be candidates for specific forms of family education and therapy. Improvements will be made in technology for assessing the construct of social skills. Schizophrenic patients will be identified who are optimally treated with low dose, depot fluphenazine and evaluation of their early response to test doses will be used to predict their long-term outcome. A longitudinal, multilevel study aims to elucidate variables which predict patterns of relapse, remission and quality of life; and disseminate variables which mark trait-like vulnerability from those which are linked to symptoms of schizophrenia.